Subscribe To

Price Alert Latest News Economic Calendar News

ALXO / ALX Oncology stock doubles on early data from phase II cancer trial

ALX Oncology Holdings Inc saw its stock value double in pre-market trading on the heels of promising interim data from a phase II study assessing the potential of its lead asset in cancer of the stomach and esophagus. The ASPEN-06 clinical evaluated the effectiveness of evorpacept in treating patients with HER2-positive gastric and gastroesophageal junction (GEJ) cancer. Read More

Demo Live Account See Partner Details

Content Topics

Oncology

Stock

Doubles

Early

Data

From

Phase

Cancer

Trial

ALXO

Posted: Oct 3 2023, 08:47

Author Name: Proactive Investors

ALXO News

By Seeking Alpha
October 9, 2023

ALX Oncology: On Right Track With Latest Interim Analysis Of Evorpacept

ALX Oncology reported positive interim results from its phase 2 study using its anti-CD47 drug for HER2-positive gastric/gastroesophageal junction can

By Proactive Investors
October 3, 2023

ALX Oncology stock doubles on early data from phase II cancer trial

ALX Oncology Holdings Inc saw its stock value double in pre-market trading on the heels of promising interim data from a phase II study assessing th

By Zacks Investment Research
August 10, 2023

ALX Oncology Holdings Inc. (ALXO) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

ALX Oncology Holdings Inc. (ALXO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled

By GlobeNewsWire
January 3, 2023

ALX Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immun

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.